Published on 21 Mar 2024 on Zacks via Yahoo Finance
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
Cardiff Oncology, Inc. CRDF is developing novel therapeutic candidates to treat various types of cancer, with an initial focus on RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC) indications.
Cardiff’s pipeline only comprises its lead investigational candidate, onvansertib, which is currently being evaluated in combination with standard-of-care (SOC) therapeutics in separate early to mid-stage studies to treat mCRC and mPDAC.
Onvansertib is an oral and small-molecule drug candidate that is highly specific for PLK1 inhibition.